Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by McAdam LLC

McAdam LLC reduced its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,997 shares of the pharmaceutical company’s stock after selling 170 shares during the period. McAdam LLC’s holdings in Vertex Pharmaceuticals were worth $813,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. OFI Invest Asset Management bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $25,000. Arlington Trust Co LLC grew its position in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 33 shares during the last quarter. Fortitude Family Office LLC bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at $30,000. Baystate Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth $34,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $396.20 on Tuesday. The firm has a market cap of $102.40 billion, a price-to-earnings ratio of 28.52, a P/E/G ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The business’s 50-day simple moving average is $411.08 and its 200-day simple moving average is $399.37. Vertex Pharmaceuticals Incorporated has a 52 week low of $320.01 and a 52 week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same quarter last year, the firm posted $3.33 earnings per share. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on VRTX shares. Oppenheimer restated an “outperform” rating and set a $500.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday, April 15th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 20th. Wolfe Research began coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, February 15th. They set an “outperform” rating and a $515.00 price objective on the stock. HC Wainwright raised their target price on Vertex Pharmaceuticals from $457.00 to $462.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Finally, Robert W. Baird lowered Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target on the stock. in a research report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $429.45.

Insiders Place Their Bets

In related news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares in the company, valued at $31,250,727.36. The disclosure for this sale can be found here. Insiders sold a total of 12,381 shares of company stock valued at $5,203,249 in the last quarter. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.